Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.
Gámez-Pozo A, Trilla-Fuertes L, Prado-Vázquez G, Chiva C, López-Vacas R, Nanni P, Berges-Soria J, Grossmann J, Díaz-Almirón M, Ciruelos E, Sabidó E, Espinosa E, Fresno Vara JÁ. Gámez-Pozo A, et al. Among authors: ciruelos e. PLoS One. 2017 Jun 8;12(6):e0178296. doi: 10.1371/journal.pone.0178296. eCollection 2017. PLoS One. 2017. PMID: 28594844 Free PMC article.
Implication of miRNA in the diagnosis and treatment of breast cancer.
Castañeda CA, Agullo-Ortuño MT, Fresno Vara JA, Cortes-Funes H, Gomez HL, Ciruelos E. Castañeda CA, et al. Among authors: ciruelos e. Expert Rev Anticancer Ther. 2011 Aug;11(8):1265-75. doi: 10.1586/era.11.40. Expert Rev Anticancer Ther. 2011. PMID: 21916580 Review.
Shotgun proteomics of archival triple-negative breast cancer samples.
Gámez-Pozo A, Ferrer NI, Ciruelos E, López-Vacas R, Martínez FG, Espinosa E, Vara JÁ. Gámez-Pozo A, et al. Among authors: ciruelos e. Proteomics Clin Appl. 2013 Apr;7(3-4):283-91. doi: 10.1002/prca.201200048. Epub 2013 Mar 6. Proteomics Clin Appl. 2013. PMID: 23436753
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
Gámez-Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López-Vacas R, Berges-Soria J, López IÁ, Margeli M, Calero JL, Farre XG, Santaballa A, Ciruelos EM, Afonso R, Lao J, Catalán G, Gallego JV, López JM, Bofill FJ, Borrego MR, Espinosa E, Vara JA, Zamora P. Gámez-Pozo A, et al. Among authors: ciruelos em. PLoS One. 2014 Oct 20;9(10):e109611. doi: 10.1371/journal.pone.0109611. eCollection 2014. PLoS One. 2014. PMID: 25330188 Free PMC article.
Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.
Gámez-Pozo A, Berges-Soria J, Arevalillo JM, Nanni P, López-Vacas R, Navarro H, Grossmann J, Castaneda CA, Main P, Díaz-Almirón M, Espinosa E, Ciruelos E, Fresno Vara JÁ. Gámez-Pozo A, et al. Among authors: ciruelos e. Cancer Res. 2015 Jun 1;75(11):2243-53. doi: 10.1158/0008-5472.CAN-14-1937. Epub 2015 Apr 16. Cancer Res. 2015. PMID: 25883093 Free article.
Functional proteomics outlines the complexity of breast cancer molecular subtypes.
Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, López-Vacas R, Díaz-Almirón M, Nanni P, Arevalillo JM, Navarro H, Grossmann J, Gayá Moreno F, Gómez Rioja R, Prado-Vázquez G, Zapater-Moros A, Main P, Feliú J, Martínez Del Prado P, Zamora P, Ciruelos E, Espinosa E, Fresno Vara JÁ. Gámez-Pozo A, et al. Among authors: ciruelos e. Sci Rep. 2017 Aug 30;7(1):10100. doi: 10.1038/s41598-017-10493-w. Sci Rep. 2017. PMID: 28855612 Free PMC article.
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.
Rojas L K, Trilla-Fuertes L, Gámez-Pozo A, Chiva C, Sepúlveda J, Manso L, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Ferrer-Gómez M, Mendiola C, Espinosa E, Sabidó E, Ciruelos E, Vara JÁF. Rojas L K, et al. Among authors: ciruelos e. Ecancermedicalscience. 2019 Jan 15;13:891. doi: 10.3332/ecancer.2019.891. eCollection 2019. Ecancermedicalscience. 2019. PMID: 30792808 Free PMC article.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, Gavilá J, Serra V, Prat A, Paré L, Céliz P, Villagrasa P, Li Y, Savoie J, Xu Z, Arteaga CL, Krop IE, Solit DB, Mills GB, Cantley LC, Winer EP, Lin NU, Rodon J. Garrido-Castro AC, et al. Among authors: ciruelos e. Breast Cancer Res. 2020 Nov 2;22(1):120. doi: 10.1186/s13058-020-01354-y. Breast Cancer Res. 2020. PMID: 33138866 Free PMC article. Clinical Trial.
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.
Villacampa G, Tolosa P, Salvador F, Sánchez-Bayona R, Villanueva L, Dienstmann R, Ciruelos E, Pascual T. Villacampa G, et al. Among authors: ciruelos e. Cancer Treat Rev. 2022 Mar;104:102352. doi: 10.1016/j.ctrv.2022.102352. Epub 2022 Feb 2. Cancer Treat Rev. 2022. PMID: 35144055 Review.
180 results